France's bioMérieux reported a rise in quarterly earnings of 3.3%, compared to the first three months of 2013, to $512.50 million.
California startup Guardant Health, which sells a cancer test based on blood samples instead of biopsies, has raised $30 million in Series B financing more than two months after garnering $10 million in a round led by Sequoia Capital.
Quest Diagnostics' revenues fell in the fourth quarter of 2013--a direct violation of its 5-point strategy including "restore growth"--but the company thinks its acquisition of prevention and wellness services outfit Summit Health will help fix those problems.
The bearish market that led Lombard Medical to delay its IPO and TriVascular Technologies to price below its range has scuttled a fundraise from diagnostics luminary Foundation Medicine.
Molecular diagnostics company Qiagen will invest $10 million to build out manufacturing capabilities at its Germantown, MD, campus by early 2015, focusing on products for women's health and infectious disease.
Abbott Laboratories has secured the FDA's blessing to launch its latest diabetes diagnostic, a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.
SQI Diagnostics has raised $4.2 million through a public offering, selling off shares and warrants to bankroll its commercialization plans.
Seattle-based Adaptive Biotechnologies announced April 7 that it has completed two rounds of financing, netting the company $120 million that it will use to expand sales of existing products and develop new ones.
Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.
A week after swaying an FDA panel with its colorectal cancer test, Exact Sciences raised $119.7 million through a stock offering, flipping 10 million shares at $12.75 each.